Evidence map›Paper›PMID 42622942›Full record

ArticleBiotechnology letters2026

Engineering Cupriavidus necator for L-threonine production.

Shuang Sha, Yanjun Li, Xiaowei Peng

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shuang Sha *State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Yanjun Li *Key Laboratory of Industrial Fermentation Microbiology of the Ministry of Education, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, 300457, China.
Xiaowei PengState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China. xwpeng@ipe.ac.cn.

Funding

National Natural Science Foundation of China 22178362
6 · The paper itself

Abstract

L-threonine plays pivotal roles in the medicine, food, and feed industries. In this work, C. necator H16 was engineered for heterotrophic and autotrophic production of L-threonine. Blocking poly-hydroxybutyrate biosynthesis redirected the carbon flux toward L-threonine, resulting in a 6.8-fold increase in L-threonine titer relative to the wild type (from 5.56 mg/L to 38.03 mg/L). Deletion of genes involved in L-threonine catabolism further minimized L-threonine loss. Moreover, strategies including sufficient precursor supply, screening of key enzymes, relief of feedback inhibition, and efficient efflux of target products were adopted for strain modification. Overexpression of key genes in the L-threonine biosynthetic pathway successfully channeled carbon flow toward L-threonine synthesis, with peak titer reaching 102.90 mg/L. Finally, in fermenter cultivation, the maximum L-threonine titer of the best L-threonine-producing strains reached 315.40 mg/L. In autotrophic fermentation the L-threonine titer was 76.26 mg/L using CO

Indexed as

Cupriavidus necatorMetabolic EngineeringThreonineAutotrophic ProcessesBiosynthetic PathwaysCarbonCarbon DioxideFermentationHydroxybutyratesPolyestersCarbonCarbon DioxideHydroxybutyratesPolyestersThreonineAutotrophic fermentationCupriavidus necatorFeedback suppressionL-threonineMetabolic engineering

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.